GlassScriptPhysician profile
Derek L Roberts
NPI 1043735509
$2,892.81
in general payments reported to CMS, 2019-2025
22 companies · $850 in 2025
The $850 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $609 · 2023: $756 · 2024: $521 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,078 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.99 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $719.34 | 2022-2025 | Azstarys |
| Abbvie INC. | $385.10 | 2021-2025 | |
| Tris Pharma INC | $304.02 | 2021-2025 | Dyanavel Xr, Quillivant |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $232.64 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $206.45 | 2022-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $185.54 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $139.54 | 2021-2025 | Spravato, Invega Sustenna |
| Collegium Pharmaceutical, INC. | $102.53 | 2025 | Jornay Pm |
| Alkermes, INC. | $99.55 | 2022-2024 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $96.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.12 | 2022-2025 | Trintellix |
| Jazz Pharmaceuticals INC. | $69.59 | 2021 | |
| Ironshore Pharmaceuticals INC. | $68.51 | 2023-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $51.32 | 2022-2025 | Rexulti |
| Brainsway USA INC | $26.05 | 2025 | Deep Tms System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $22.14 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $20.22 | 2025 | Austedo Xr |
| Lundbeck LLC | $19.80 | 2024 | Rexulti |
| Neos Therapeutics, LP | $19.52 | 2023 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $18.33 | 2023 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $14.81 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.